News Releases

Year

17 Jul '19

Cortexyme’s Approach to Addressing a Key Underlying Cause of Alzheimer’s Detailed at Alzheimer’s Association International Conference 2019

-- Rationale and design of the GAIN trial discussed in AAIC news briefing earlier this morning -- In Phase 1b testing, COR388 was associated with reductions in markers of inflammation and pathological ApoE fragmentation SOUTH SAN FRANCISCO, Calif. & LOS ANGELES --(BUSINESS WIRE)--Jul.

PDF Version

10 Jul '19

Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019

- Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 10, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to

PDF Version

19 Jun '19

Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 19, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four

PDF Version

10 Jun '19

Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019

-- Event will be webcast, with Cortexyme presentation expected to start at 2:05 p.m. EDT tomorrow afternoon SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that Casey Lynch , the company’s chief executive officer, chairman, and

PDF Version

13 May '19

Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 13, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the

PDF Version

08 May '19

Cortexyme, Inc. Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it

PDF Version

16 Apr '19

Cortexyme Announces Phase 2/3 Clinical Trial Based on Transformational Understanding of Alzheimer’s Disease Now Open for Enrollment

The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease Researchers seek more than 500 participants in the United States and Europe; visit www.GAINtrial.com for information SOUTH SAN FRANCISCO, Calif.--(

PDF Version

04 Apr '19

Cortexyme elects Christopher J. Senner to its Board of Directors

SOUTH SAN FRANCISCO, Calif. — Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s disease (AD) and other degenerative diseases, today announced the election of veteran

PDF Version

25 Mar '19

Cortexyme to Present Preclinical and Clinical Data Supporting its Novel Investigational Alzheimer's Treatment at AD/PD 2019

Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s disease (AD) and other degenerative diseases, today announced it will convene an educational session at AD/PD™ 2019,

PDF Version

11 Feb '19

Biopharma Veterans Kevin Young and Una Ryan Join Cortexyme Board of Directors

SOUTH SAN FRANCISCO, Calif. — February 11, 2019 — Cortexyme, Inc., a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative disorders, today announced the election of Kevin Young, CBE and Una Ryan, OBE,

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12